Hong Kong Stock News

Hang Lung Properties (SEHK:101) is back in focus after its first half 2026 results, which showed higher sales along with lower net income and earnings per share, as well as an affirmed interim dividend announcement. See our latest analysis for Hang Lung Properties. At a HK$7.48 share price, Hang Lung Properties has seen a 5.35% 1 month share price return but is still down 14.22% year to date, with the 1 year total shareholder return declining 2.42% and the 5 year total shareholder return...

Viewing insider transactions for P.B. Group Limited's ( HKG:8331 ) over the last year, we see that insiders were net...

Xinyi Glass Holdings (SEHK:868) just reported half year 2026 earnings that showed lower sales but higher net income and earnings per share. This mix of top line pressure and profitability improvement is now in focus for investors. See our latest analysis for Xinyi Glass Holdings. At a latest share price of HK$9.455, Xinyi Glass Holdings has a 1 month share price return of 10.84% and a 3 month share price return that is down 16.40%. The 1 year total shareholder return of 15.30% contrasts with...

While Towngas Smart Energy Company Limited ( HKG:1083 ) might not have the largest market cap around , it received a...

What Laopu Gold’s New Guidance Tells You Laopu Gold (SEHK:6181) has issued new consolidated earnings guidance for the first half of 2026, flagging a sharp year over year rise in sales and revenue that investors will be watching closely. The company now expects tax inclusive sales between RMB 22,700 million and RMB 23,350 million and revenue between RMB 19,800 million and RMB 20,450 million, which it guided at roughly 60% to 66% above the prior year period. See our latest analysis for Laopu...

Even though Mediwelcome Healthcare Management & Technology Inc. ( HKG:2159 ) posted strong earnings recently, the stock...

The market rallied behind Lever Style Corporation's ( HKG:1346 ) stock, leading do a rise in the share price after its...

While Wasion Holdings Limited ( HKG:3393 ) might not have the largest market cap around , it saw a decent share price...

Why the new profit guidance matters for China Youran Dairy Group China Youran Dairy Group (SEHK:9858) told investors it expects a profit of RMB 739 million to RMB 903 million for the first half of 2026, compared with a RMB 297 million loss a year earlier. The company linked this turnaround to smaller revaluation losses on biological assets, higher culled cow prices, lower feed costs and higher milk yields, as well as improved sales volumes and gross profit from its core operations. See our...

Why Legend Holdings stock is back in focus Legend Holdings (SEHK:3396) has drawn attention after issuing preliminary earnings guidance for the first half of 2026, pointing to net profit of at least CN¥2,000 million, up at least 186% year on year. The company attributes this shift mainly to its industrial incubations and investments segment moving from loss to profit, helped by a recovery in capital markets. For investors, the guidance offers a fresh data point on how the group’s diversified...

Hong Kong Exchanges and Clearing (SEHK:388) has introduced a Five-Year China Government Bond Futures contract, giving investors a new listed tool to manage interest rate and duration exposure to Chinese Mainland government bonds. See our latest analysis for Hong Kong Exchanges and Clearing. The new China Government Bond Futures launch arrives at a time when Hong Kong Exchanges and Clearing’s share price has gained 8.26% over the past month, although the 1-year total shareholder return is...

In August 2026, InnoCare Pharma announced that its BTK inhibitor orelabrutinib, combined with BCL2 inhibitor mesutoclax, received Breakthrough Therapy Designation from China’s CDE for previously treated marginal zone lymphoma, following clinical data showing a 100% overall response rate and a favorable safety profile. This recognition, alongside earlier positive Phase III results for TYK2 inhibitor fadeucravacitinib in moderate-to-severe plaque psoriasis, underscores InnoCare’s push to...

Techtronic Industries (SEHK:669) has drawn fresh attention after reporting half year 2026 earnings alongside progress on its share buyback program, giving investors new data points on sales, profitability, and capital allocation. See our latest analysis for Techtronic Industries. Techtronic Industries’ latest earnings and buyback update has coincided with strong momentum in the stock, with a 30 day share price return of 16.63% and a year to date share price return of 58.40%. The 3 year total...

Why Simcere Pharmaceutical Group Stock Is Back in Focus Simcere Pharmaceutical Group (SEHK:2096) is drawing investor attention after issuing new consolidated earnings guidance for the six months to 30 June 2026, highlighting projected year on year changes in both revenue and profit. See our latest analysis for Simcere Pharmaceutical Group. Against this earnings guidance backdrop, Simcere Pharmaceutical Group’s recent momentum has been steady, with a 30 day share price return of 2.98% and a 90...

Insiders who bought CN¥13.5m worth of Teamway International Group Holdings Limited ( HKG:1239 ) stock in the last year...

Fosun International (SEHK:656) drew fresh attention on 29 July 2026 after issuing earnings guidance that points to profit attributable to shareholders of RMB 1.5b to RMB 1.8b for the first half of 2026. See our latest analysis for Fosun International. The guidance appears to have shifted sentiment around Fosun International, with a 1-day share price return of 7.38% and a 30-day share price return of 33.60% lifting the stock to HK$5.09, even though the 1-year total shareholder return is still...

China’s decision to relax its earlier regulatory pressure on Panama following a dispute over CK Hutchison Holdings (SEHK:1) terminal concessions at the Panama Canal has refocused attention on the group’s ports and related services operations. See our latest analysis for CK Hutchison Holdings. At a share price of HK$73.25, CK Hutchison Holdings has a year to date share price return of 35.65%, while its 1 year total shareholder return of 47.68% and 3 year total shareholder return of 97.51%...

HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus Shanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with...

The Asian markets have been experiencing a mix of geopolitical influences and economic indicators, contributing to a complex investment landscape. In such conditions, penny stocks—despite their somewhat outdated name—remain an intriguing area for investors seeking opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer potential value and growth that may not be as readily available with larger firms. In this article, we explore three Asian penny...

HBM Holdings (SEHK:2142) has drawn fresh attention after Harbour BioMed announced two company level developments. Investors are weighing the appointment of a new president for its metabolic franchise and a collaboration with China National Pharmaceutical Group. See our latest analysis for HBM Holdings. At a share price of HK$14.19, HBM Holdings has seen strong recent momentum, with a 21.8% 1 month share price return and a 17.5% year to date share price return, while the 3 year total...

The appointment of Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer gives Ascentage Pharma Group International (SEHK:6855) dedicated leadership for global business development and ex-China commercialization. See our latest analysis for Ascentage Pharma Group International. Ascentage Pharma Group International’s recent executive appointments come as the stock shows a mixed picture, with the 7 day share price return of 7.81% and 30 day share price return of...

Swire Pacific went into this earnings day with the stock up roughly 19% over the past month and trading on a premium P/E of about 15x. That set the bar high. The headline today is that the company delivered record recurring underlying profit of about HK$7.8b in H1 2026 and lifted its interim dividend by 15%. For a long term Hong Kong conglomerate story built on property, beverages and aviation cash flows, that kind of profit and dividend combination is what moves the needle. The rest of the...

Asia Cement (China) Holdings went into this earnings print with the stock at HK$1.78, modestly up over the past month but still weaker over the past quarter. The headline from Q2 is not the top line; it is the profit squeeze. Management booked CNY1,271.1m in revenue yet still reported a net loss of CNY13.0m and a loss per share. For a heavy industrial like cement, where fixed costs are unforgiving, that shift into the red is what matters for a multi year view on margins and capacity...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see PCCW Limited...